Your browser doesn't support javascript.
loading
Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan, Thomas S Y; Hwang, Yu-Yan; Khong, Pek-Lan; Leung, Anskar Y H; Chim, Chor-Sang; Tse, Eric W C; Kwong, Yok-Lam.
Affiliation
  • Chan TSY; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Hwang YY; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Khong PL; Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China.
  • Leung AYH; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Chim CS; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Tse EWC; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Kwong YL; Department of Medicine, Queen Mary Hospital, Hong Kong, China.
Hematol Oncol ; 38(5): 726-736, 2020 Dec.
Article in En | MEDLINE | ID: mdl-32786092
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Antineoplastic Combined Chemotherapy Protocols Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2020 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Antineoplastic Combined Chemotherapy Protocols Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2020 Type: Article Affiliation country: China